The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 7 – 10 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented.

Myeloma Patients Europe (MPE) will attend the meeting to learn and share updates about the most significant developments in myeloma and AL amyloidosis. MPE will also meet with members, sponsors, European and US advocacy groups, myeloma doctors, researchers and other stakeholders to discuss ongoing projects and future collaborations.

Stay tuned to our social media accounts (Facebook, LinkedIn, Twitter) for the latest information during the conference. MPE will be filming and posting interviews with leading researchers throughout the Meeting.

MPE will also host an ASH highlights webinar on 18 December at 17:00 CET.

MPE´s Head of Medical Education and Scientific Engagement, Solène Clavreul, is also a co-author on a poster being presented on Sunday, 8 December. The poster is entitled Examining Discrepancies in Perspectives of Healthcare Providers and Patients With Relapsed/Refractory Multiple Myeloma on Novel Therapies Across Diverse Clinical Landscapes: An International Prospective Study. You can find further information here.

PROGRAMME HIGHLIGHTS

The programme for myeloma and AL amyloidosis this year is extensive and rich, with a range of research focusing on the science underlying myeloma and on the anti-myeloma effect of existing and new medicines. Given the extensive programme, it is difficult to summarise every presentation, but MPE believes the following myeloma and AL amyloidosis data will be of greatest interest to patients:

AL Amyloidosis

There will be several presentations on the treatment of AL amyloidosis. In particular, results of the ISAMYP study will be presented. The study conducted in multiples sites in France and Australia is evaluating the efficacy and safety of the combination of isatuximab, pomalidomide and dexamethasone (IsaPd), in AL amyloidosis patients with suboptimal response to previous therapy or at relapse.

• Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG. Click here for details. Monday, December 9, 2024: 3:30 PM (GMT-8)

Smouldering myeloma

There are few presentations of interest that will focus on the outcomes of patients with smouldering myeloma. In the years to come, it will be important to understand when it is best to start treatment. The Aquila study is investigating whether daratumumab monotherapy could delay progression to myeloma compared active monitoring in patients with high-risk smouldering myeloma and preliminary results will be presented during the meeting.

• Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smouldering Multiple Myeloma: Primary Results of the Aquila Study. Click here for details. Monday, December 9, 2024: 11:30 AM (GMT-8)

The CAR PRISM study is investigating, for the first time, the safety and efficacy of the use of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy in patients with high-risk smouldering myeloma, without induction therapy, and will present the results observed in the first 6 patients of the study.

• Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smouldering Myeloma. Click here for details. Monday, December 9, 2024: 4:30 PM (GMT-8)

Myeloma

There will be several talks dedicated to the treatment of newly diagnosed myeloma. As tolerance to treatment vary among patients, the IFM2017-03 study is investigating the efficacy and safety of the daratumumab, lenalidomide and dexamethasone combination without long term dexamethasone compared to a lenalidomide and dexamethasone combination with long term dexamethasone in a frail population of patients with newly diagnosed myeloma. Positive results may lead to a decreased use of dexamethasone and therefore an improved quality of life for patients.

• The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma. Click here for details. Monday, December 9, 2024: 11:45 AM (GMT-8)

Some results of the MajesTEC-5 study on the addition of teclistamab to daratumumab-based induction regimens before stem cell transplant will be presented. These combinations are hoped to increase long-term disease-free survival of newly diagnosed myeloma patients.

• Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. Click here for details. Sunday, December 8, 2024: 9:30 AM (GMT-8)

The ASH congress will also see a range of oral and poster presentations exploring the role of CAR T-cell therapies and bispecific antibodies used as single agents or in combination with already approved treatments, and newly developed trispecific antibodies in the treatment of relapse refractory myeloma.

• Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial. Click here for details. Monday, December 9, 2024: 5:30 PM (GMT-8)
• Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM). Click here for details. Monday, December 9, 2024: 5:15 PM (GMT-8)
• First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Click here for details. (GMT-8)

Results on other types of treatments will be also presented. If approved, these new agents and combinations will provide more treatment options for relapse refractory myeloma patients. In particular, the results of a study investigating the safety and efficacy of the Cereblon E3 ligase modulatory drug (CELMoD) mezigdomide (a new generation of IMID) in combination with dexamethasone and bortezomib or carfilzomib will be presented.

• Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial. Click here for details. Monday, December 9, 2024: 5:30 PM (GMT-8)

The safety and efficacy results of a new oral agent called inobrodib will also be presented. Inobrodib is a small molecule inhibitor drug which disrupts the growth of cancer cells. This treatment could provide patients with an oral-only treatment option at late treatment lines.

• Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Click here for details. Monday, December 9, 2024: 5:00 PM (GMT-8)

As treatment options can become burdensome for patients and leading to cumulative side effects, it is important to understand when it is safe to stop treatment to preserve quality of life and clinical outcomes. A study conducted in Germany investigated patients’ preferences on treatment free intervals to better tailor treatment plans to patients’ needs and desires.

• Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations. Click here for details. Saturday, December 7, 2024: 2:15 PM